Tag Archives: TSX:PLI
RBC Capital Thinks ProMetic Life’s Stock is Going to Recover
The Healthcare company, ProMetic Life (PLI – Research Report), has received a rating update from a Wall Street analyst today. Analyst Douglas Miehm from RBC Capital remains bullish on the stock and has a C$0.70 price target. According to TipRanks.com,
Canaccord Genuity Sticks to Its Buy Rating for ProMetic Life (PLI)
ProMetic Life (TSX: PLI), the Healthcare company, has received a rating update from a Wall Street analyst today. Analyst Dewey Steadman from Canaccord Genuity rated ProMetic Life (TSX: PLI) a Buy, setting a C$2 price target. Steadman commented: “We think
ProMetic Life Receives a Buy from Cantor Fitzgerald
Yesterday, an analyst has provided a rating update for the Healthcare company, ProMetic Life (TSX: PLI). Analyst Mara Goldstein from Cantor Fitzgerald remains bullish on the stock. Goldstein said: “PLI.TO prioritization of IPF and Alstrom’s Syndrome for PBI-4050 and back-
ProMetic Life Gets a Buy Rating from Cantor Fitzgerald
Yesterday, an analyst has provided a rating update for the Healthcare company, ProMetic Life (TSX: PLI). Analyst Mara Goldstein from Cantor Fitzgerald rated ProMetic Life (TSX: PLI) a Buy. Goldstein said: “Comprehensive Phase III. Prometic confirmed plans to initiate a
ProMetic Life Received its Third Buy in a Row
Analysts seem to be optimistic about ProMetic Life (TSX: PLI) lately with another positive rating update this time from Canaccord Genuity. Today, analyst Neil Maruoka gave a Buy rating to PLI and set a C$4 price target. Maruoka noted: “We
Cantor Fitzgerald Thinks ProMetic Life’s Stock is Going to Recover
In a new note to investors yesterday, an analyst has provided a rating update for the Healthcare company, ProMetic Life (TSX: PLI). The company received a Buy rating from Cantor Fitzgerald’s analyst Mara Goldstein, with a C$4 price target. According
